December 2013 in “Estudo Geral (Universidade de Coimbra)” Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
3 citations
,
April 2020 in “PubMed” Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.
38 citations
,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
December 2013 in “Open Access Macedonian Journal of Medical Sciences” A woman's excessive hair growth and high testosterone were caused by a rare ovarian tumor, which was successfully treated with surgery.
2 citations
,
December 2013 in “Cancer Research” Some early breast cancer patients have long-term hair loss after chemotherapy, especially older and postmenopausal women.
3 citations
,
August 2021 in “Journal of Cosmetic Dermatology” Non-ablative Er:YAG laser effectively treats hair loss with high patient satisfaction and no side effects.
9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
December 2013 in “Macedonian Journal of Medical Sciences” Ovarian steroid cell tumors should be considered in adults with hirsutism and high testosterone, with surgery as the main treatment.
19 citations
,
June 1997 in “The Journal of Clinical Endocrinology & Metabolism” The treatment successfully lowered testosterone levels and reduced symptoms.
3 citations
,
April 1977 in “PubMed” The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.
15 citations
,
July 2023 in “EClinicalMedicine” ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.
Non-ablative Er:YAG-laser treatment helps improve life quality for menopausal women with hair loss.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
20 citations
,
January 1999 in “Current Pharmaceutical Design” Antiandrogen therapy is effective and well tolerated for treating women's androgenic disorders like hirsutism, acne, and hair loss.
14 citations
,
January 1980 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Both treatments reduced androgen levels and hair growth in women with hirsutism.
8 citations
,
June 2022 in “Cancers” Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.
1 citations
,
September 1981 in “PubMed” Cyproterone acetate effectively treats virilized women, especially under 35, despite some side effects.
48 citations
,
September 2013 in “Oncologist” Endocrine therapies for cancer significantly increase the risk of hair loss.
1 citations
,
November 2024 in “Expert Opinion on Drug Safety” Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.
Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair growth cells and aiding self-repair.
1 citations
,
March 2023 in “Medicine” The combination therapy is effective and well-tolerated for treating esophageal cancer.
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.
March 2023 in “Journal of Cosmetic Dermatology” Low-dose oral minoxidil improved hair growth when topical treatments failed.
3 citations
,
July 2014 in “Indian Journal of Surgery” Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.
2 citations
,
October 2015 in “The New England Journal of Medicine” The woman's surgery lowered her testosterone and improved scalp hair loss but did not change her excessive body hair.
1 citations
,
May 2025 in “BMC Cancer” CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.